Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT
NCT00586690
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
47
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma
Interventions
DEVICE:
NK Cell infusion using CD56 monoclonal antibody
PROCEDURE:
Donor Apheresis
Sponsor
David Rizzieri, MD